Literature DB >> 16831091

Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.

Vesna Blazevic1, Andres Männik, Maria Malm, Rein Sikut, Minna Valtavaara, Urve Toots, Mart Ustav, Kai Krohn.   

Abstract

A multiHIV fusion gene expressing an antigenic fusion protein composed of regulatory HIV-1 proteins Rev, Nef, and Tat, as well as Gag p17/p24 and a stretch of 11 cytotoxic T lymphocyte (CTL) epitope clusters from Pol and Env, was cloned into a novel DNA vector named the Gene Transport Unit (GTU). A mouse H-2(d)-restricted HIV-1 gp120 epitope (RGPGRAFVTI) was cloned into the fusion gene as well. In addition to the HIV- 1 genes the GTU codes for a nuclear anchoring protein (bovine papilloma virus E2), ensuring the long maintenance of the vector and a high expression level of the selected immunogens. BALB/c mice were immunized with the GTU-MultiHIV DNA construct by different routes and regimens of immunization to assess the immunogenicity of the DNA vaccine in vivo. Mice developed strong CD8(+) CTL responses to HIV-1 Env and Gag measured by an ELISPOT-IFN-gamma assay and chromium release assay. In addition, T cell responses to regulatory proteins Rev, Nef, and Tat were induced. Antibody responses were detected to each of the HIV antigens encoded by the DNA construct. Minimal doses of the GTU-MultiHIV DNA delivered by gene gun were potent in inducing significant HIV-specific CTL responses. The equivalent doses of the conventional plasmid expressing MultiHIV DNA delivered by gene gun failed to do so. An ideal DNA vaccine should yield high expression of the viral antigens for a prolonged period of time, and expression of the multiple viral antigens is probably required for the induction of a broad and protective immune response. The GTU-MultiHIV DNA vaccine described is a good vaccine candidate that meets the above criteria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831091     DOI: 10.1089/aid.2006.22.667

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.

Authors:  Petr O Ilyinskii; Anatoli B Meriin; Vladimir L Gabai; Evgeny V Usachev; Alexei G Prilipov; Galini Thoidis; Alexander M Shneider
Journal:  Protein Sci       Date:  2008-04-14       Impact factor: 6.725

2.  Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.

Authors:  Jamie F S Mann; Paul F McKay; Anezka Fiserova; Katja Klein; Alethea Cope; Paul Rogers; Julie Swales; Michael S Seaman; Behazine Combadiere; Robin J Shattock
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

3.  Innate Molecular and Cellular Signature in the Skin Preceding Long-Lasting T Cell Responses after Electroporated DNA Vaccination.

Authors:  Lucille Adam; Nicolas Tchitchek; Biliana Todorova; Pierre Rosenbaum; Candie Joly; Candice Poux; Catherine Chapon; Anna-Lena Spetz; Mart Ustav; Roger Le Grand; Frédéric Martinon
Journal:  J Immunol       Date:  2020-05-08       Impact factor: 5.422

4.  Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies.

Authors:  Kevin Hollevoet; Elien De Smidt; Nick Geukens; Paul Declerck
Journal:  Oncotarget       Date:  2018-02-06

5.  Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques.

Authors:  Biliana Todorova; Lucille Adam; Slobodan Culina; Raphaël Boisgard; Frédéric Martinon; Antonio Cosma; Mart Ustav; Thierry Kortulewski; Roger Le Grand; Catherine Chapon
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

6.  Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.

Authors:  Hannah Mary Cheeseman; Suzanne Day; Leon Robert McFarlane; Sue Fleck; Aleisha Miller; Tom Cole; Nelson Sousa-Santos; Alethea Cope; Deniz Cizmeci; Monica Tolazzi; Edith Hwekwete; Drew Hannaman; Sven Kratochvil; Paul Francis McKay; Amy W Chung; Stephen J Kent; Adrian Cook; Gabriella Scarlatti; Sonya Abraham; Behazine Combadiere; Sheena McCormack; David John Lewis; Robin John Shattock
Journal:  Hum Gene Ther       Date:  2018-09       Impact factor: 5.695

Review 7.  Strategies for Immunomonitoring after Vaccination and during Infection.

Authors:  Lucille Adam; Pierre Rosenbaum; Olivia Bonduelle; Behazine Combadière
Journal:  Vaccines (Basel)       Date:  2021-04-09

Review 8.  Developments in HIV-1 immunotherapy and therapeutic vaccination.

Authors:  Peter Lawrence Smith; Helen Tanner; Angus Dalgleish
Journal:  F1000Prime Rep       Date:  2014-06-02

9.  Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.

Authors:  G Haidari; A Cope; A Miller; S Venables; C Yan; H Ridgers; K Reijonen; D Hannaman; A Spentzou; P Hayes; G Bouliotis; A Vogt; S Joseph; B Combadiere; S McCormack; R J Shattock
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.